Hepatocellular Carcinoma Clinical Trial
Official title:
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
It has been shown previously that gene expression profiling signature (a set of dysregulated
genes) can be used for molecular classification, diagnosis, and prognosis of several types of
cancers. In This study the hypothesise that resistant tumor may be due to genetic mutations
and/or other alternative pathways that could be the reason to overcome the Sorafenib and
still proliferate.
Primary objectives To evaluate the primary and secondary potential mechanisms by which HCC
patients on Sorafenib treatment would be resistant to therapy and also identify the favorable
genetic makeup of patients responding to treatment.
Measures of primary outcome:
- cDNA microarray analysis on the MAP kinase pathway.
- mRNA quantification of genetic expression (RT-PCR) for identification of upregulated
genes, and confirmed by corresponding proteomic testing (by Mass Spectroscopy) in the
serum for potential serum markers. Secondary Objectives Progression free survival: Time
to disease progression in patients in Saudi Arabia with HCC receiving Sorafenib:
[defined as time, in weeks, from the baseline visit to progression of the disease or
death from any cause] will be diagnosed using the RECIST criteria based on a trimestrial
abdominal CT evaluation.
- Survival rates and Predictors of survival:
- Survival defined as the time from baseline visit to death from any cause [in
weeks].
- Variables identified in multivariate regression analysis from overall treated
patients independently associated with survival till study completion or death.
Justification and Value to the Kingdom Sorafenib in the treatment of advanced HCC
is a recent development. Since the only current effective treatment for advanced
HCC is resection or transplantation and the list for these procedures are
ever-growing due to the confounding effect of the lack of infrastructure in the
Kingdom, selecting treatment for patients who are more likely to respond to
Sorafenib treatment The Long-Term Comprehensive National Plan for Science,
Technology and Innovation will help to reduce costs of managing HCC. Among Saudi
Arabia population, there are a unique set of patients here (e.g. non-alcohol
related HCC, genotype 4 HCV patients and genotype D HBV patients, high percentage
of obese patients i.e. NASH) which is different from other parts of the world.
There is increasing incidence of HCC in Saudi Arabia. Due to available expertise in
management of HCC patients in the participating institutions in the study, this
project will represent a bridge for the transfer of technology so that our research
staff and doctors will have more expertise in carrying out these techniques
independently. This study will also run in parallel to the on-going initiative to
start a HCC biobanking establishment which will provide the samples needed to carry
out our genetic studies in future. Finally, since the use of Sorafenib (at present,
the only approved treatment for advanced HCC) in the treatment of advanced HCC is a
new field, the findings of our study will have important implications in the
management of HCC, both locally and internationally.
HCC is the third most common cancer in Saudi Arabia. In 2001, HCC was the second most common
cancer affecting Saudi males and the eighth most common cancer affecting females. Most of
patients (90%) present at a more advanced stage when symptoms prevail.
Given the high prevalence of HCC in the Kingdom, it is pertinent to study why some patients
are resistant to Sorafenib compared to others. Elucidation of the differences in mechanisms
among responders and non-responders to Sorafenib therapy will enable physicians to make
better decisions in terms of treating Saudi HCC patients.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Male or female patient over 18 years of age - Patient who have a life expectancy of at least 12 weeks - Biopsy proven diagnosis of hepatocellular carcinoma - Liver lesions are visible and measurable of at least 3 cm in size - Advanced HCC, defined by the presence of one of the followings: - Vascular invasion - HCC with cancer-related symptoms with ECOG Score of 0, 1 or 2 - Progression after resection or local ablation and not for further curative therapies - Cirrhotic status of Child-Pugh class A and B (score = 8) - The following laboratory parameters: - Platelet count > 50 X 109 /L - Hemoglobin > 85 g/L - Total bilirubin < 51.3 umol/L - ALT and AST < 5X upper limit of normal - Amylase and lipase < 1.5 X the upper limit of normal - Serum creatinine < 1.5 X the upper limit of normal - Prothrombin time (PT) international normalized ratio (INR) < 2.3 or PT < 6 seconds above control. Patients who are being therapeutically anticoagulated with an agent such as Coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. - Able to give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice. - Any institution/centre specific criteria that must be adhered to for the patient to be eligible. Exclusion Criteria: Previous or concurrent cancer that is distinct in primary site or histology from HCC. Except: - Cervical carcinoma in situ - Prostate cancer with good prognosis - Treated basal cell carcinoma - Superficial bladder tumors (Ta, Tis & T1) - Any cancer curatively treated 3 years prior to entry is permitted. - A Child-Pugh rating of C at entry - An ECOG performance score of 3 or 4 at entry - Extensive extra-hepatic disease - Tumor volume > 50% of liver volume - Contraindication to angiography or selective visceral catheterization - Any bleeding diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agent - Severe peripheral vascular disease precluding catheterization - History of severe allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically - Platelet count < 30,000 or < 50% prothrombin activity - Renal failure requiring hemo-or peritoneal dialysis - Pulmonary insufficiency (clinically evident history of chronic obstructive pulmonary disease) - History of cardiac disease: - Congestive heart failure > New York Heart Association (NYHA) class2 - Active coronary artery disease - Uncontrolled hypertension - Active clinically serious infection(s) - Known history of human immunodeficiency virus (HIV) infection - Patient with clinically significant gastrointestinal bleeding within 30 days prior to study entry - History of organ allograft/transplantation - Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results - Known or suspected allergy to the investigational agent or any agent given in association with this trial - Patients unable to swallow oral medications - Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study - Pregnant or breast-feeding patients - Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. - Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial. Excluded therapies and medications - previous and concomitant: - Prior use of any systemic anti-cancer chemotherapy for HCC - Prior use of systemic investigational agents for HCC - Prior use of Raf-kinase inhibitors (RKI), VEGF inhibitors, EMK inhibitors or Farnesyl transferase inhibitors - Major surgery within 4 weeks of start of the study drug - Use of biologic response modifiers, such as granulocytes colony-stimulating factor (G-CSF) within 3 weeks prior to study entry (G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator; however they may not be substituted for a required dose reduction) - Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 1 month prior to the study or during the study. - Autologous bone marrow transplant or stem cell rescues within four months of start of study drug - Concomitant treatment with rifampin and St John's wort |
Country | Name | City | State |
---|---|---|---|
Saudi Arabia | King Saud University Medical City | Riyadh |
Lead Sponsor | Collaborator |
---|---|
King Saud University | King Faisal Specialist Hospital & Research Center |
Saudi Arabia,
Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14. — View Citation
Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612. — View Citation
Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0. — View Citation
Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006 Dec 15;66(24):11851-8. — View Citation
Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008 Jan;47(1):82-9. — View Citation
Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181-200. Review. — View Citation
Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, Opolon P, Poynard T. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis? Aliment Pharmacol Ther. 1998 Feb;12(2):111-26. — View Citation
McKeage K, Wagstaff AJ. Sorafenib: in advanced renal cancer. Drugs. 2007;67(3):475-83; discussion 484-5. Review. — View Citation
Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613. — View Citation
Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004 Apr;126(4):1005-14. — View Citation
Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol. 2008 Apr;15(4):1008-14. doi: 10.1245/s10434-007-9705-0. Epub 2008 Jan 31. Review. — View Citation
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. — View Citation
Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22. — View Citation
* Note: There are 13 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall and disease-free survival genes. | Survival analysis | 10 years | |
Secondary | The predictors of survival ( response to Sorafenib ) | Survival analysis | 10 years | |
Secondary | Potential genetic targets for resistance. | Samples will be sequenced using second generation sequencing comparison between, before and after therapy signature will be identified. | 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |